Tickers

1. Composite Trajectory Verdict

Given PATK's acquisitive, cyclical manufacturing and distribution model, all three statements carry weight, but the cash flow statement is most critical for assessing its ability to fund acquisitions, dividends, and share repurchases while navigating industry downturns.

Composite Trajectory: Mixed

Annual FY2025 results show improving profitability: revenue grew 6% to $3.95B, gross margin expanded 60 bps to 23.1%, and operating margin rose 10 bps to 7.0% (10-K FY2025, Income Statement). However, quarterly trends deteriorated in the first half of 2026: revenue declined 1% YoY in both Q1 and Q2, gross margin compressed 10 bps in Q2, and operating margin fell 90 bps in Q2 and 40 bps YTD (10-Q Q1 2026, 10-Q Q2 2026, Income Statement). Operating cash flow collapsed 64% YTD to $68.9M from $189.5M due to a $112.8M working capital cash outflow (10-Q Q2 2026, Cash Flows). Leverage increased with total net leverage rising to 2.97x from 2.62x at year-end 2025, and equity declined 4.5% as $106M in share repurchases and $31M in dividends were funded partly by revolver borrowings (10-Q Q2 2026, Balance Sheet, Liquidity). The pending LCI merger adds further uncertainty.

2. Red Flags

• Operating cash flow dropped 64% YTD Q2 2026 to $68.9M vs $189.5M YTD Q2 2025, driven by a $112.8M working capital cash outflow compared to a $27.7M inflow a year earlier (10-Q Q2 2026, Cash Flows).
• Receivables surged 49% to $276.9M and inventory rose 10% to $653.3M at June 28, 2026 vs December 31, 2025, funded by $130M net revolver borrowings (10-Q Q2 2026, Balance Sheet).
• Total net leverage increased to 2.97x at June 28, 2026 from 2.62x at December 31, 2025; secured net leverage rose to 0.61x from 0.34x (10-Q Q2 2026, Liquidity).
• Quarterly revenue declined 1% YoY in both Q1 2026 ($997.2M vs $1,003.4M) and Q2 2026 ($1,041.7M vs $1,047.6M) with operating margin compression of 90 bps in Q2 (10-Q Q1 2026, 10-Q Q2 2026, Income Statement).
• Shareholders' equity fell 4.5% to $1.13B in the first half of 2026 as $106.1M in share repurchases and $31.2M in dividends exceeded net income of $82.9M (10-Q Q2 2026, Equity, Cash Flows).
• "Other expenses" of $24.4M for a legal settlement appeared in FY2025 and Q2 2025 but not in 2026 periods, distorting year-over-year net income comparisons (10-K FY2025, 10-Q Q2 2026, Income Statement).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual FY2025 showed improvement: net sales rose 6% to $3.95B, gross profit increased 9% to $912.9M with margin expanding 60 bps to 23.1%, and operating income grew 7% to $276.0M with margin up 10 bps to 7.0% (10-K FY2025, Income Statement). Net income fell 2% to $135.1M due to a $24.4M legal settlement recorded in other expenses. In contrast, the first half of 2026 showed deterioration: YTD revenue declined 1% to $2.04B, gross margin compressed 10 bps to 23.3%, operating margin fell 40 bps to 7.0%, and operating income dropped 7% to $141.8M (10-Q Q2 2026, Income Statement). Q2 2026 alone saw operating margin fall 90 bps to 7.4%. Net income rose 17% YTD to $82.9M and 34% in Q2 to $43.4M, but only because the prior year included the $24.4M settlement charge. Segment trends diverged: manufacturing operating income was flat YTD while distribution operating income fell 27% (10-Q Q2 2026, Segment Reporting).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

FY2025 operating cash flow was essentially flat at $329.4M vs $326.8M in FY2024 (10-K FY2025, Cash Flows). However, YTD Q2 2026 operating cash flow plunged 64% to $68.9M from $189.5M in YTD Q2 2025 (10-Q Q2 2026, Cash Flows). The decline was driven by a $112.8M cash outflow from changes in operating assets and liabilities (net of acquisitions) versus a $27.7M inflow a year earlier, primarily from a $91M increase in receivables and $56.5M increase in inventories (10-Q Q2 2026, Cash Flows). Investing outflows decreased to $44.2M from $86.6M due to lower acquisition spending ($7.3M vs $48.1M). Financing activities shifted to net repayments of $22.0M vs $114.4M, but this masked $130M in net revolver borrowings that funded $106.1M in share repurchases and $31.2M in dividends (10-Q Q2 2026, Cash Flows). Free cash flow (operating cash flow less CapEx) was $32.3M YTD Q2 2026 vs $151.0M YTD Q2 2025.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

From FY2024 to FY2025, the balance sheet improved modestly: total assets rose 1.8% to $3.08B, total liabilities were flat at $1.89B, equity grew 5% to $1.18B, and secured net leverage was a low 0.34x (10-K FY2025, Balance Sheet, Liquidity). In the first half of 2026, the trend reversed: total assets grew 4.4% to $3.21B but liabilities jumped 10% to $2.08B while equity fell 4.5% to $1.13B (10-Q Q2 2026, Balance Sheet). Long-term debt increased 10% to $1.41B as the revolver balance rose to $205M from $75M. Current liabilities grew 10% to $383.3M with accounts payable up 17% to $224.5M. Total net leverage rose to 2.97x from 2.62x, though both secured net leverage (0.61x) and interest coverage (6.58x) remained well within covenant limits of 2.75x and 3.00x respectively (10-Q Q2 2026, Liquidity). Goodwill and intangibles declined slightly due to amortization and purchase accounting adjustments.

6. Data Gaps

• Quarterly data for Q3 and Q4 2025 not provided (only Q1-Q2 2025 and Q1-Q2 2026 available), preventing full quarterly trend analysis for FY2025
• No segment-level cash flow data provided to assess manufacturing vs distribution cash generation
• Post-merger pro forma financials for the pending LCI transaction not available
• Full-year 2026 guidance or updated outlook not included in filings
• Detailed breakdown of the $24.4M legal settlement (timing, insurance recovery, tax treatment) not fully disclosed